Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq(The Ohio State University), Renier J. Brentjens(Roswell Park Comprehensive Cancer Center)
Cited by 1,440
Related Papers
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
|Blood|2016|398
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
|Scientific Reports|2017|397
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
|Blood|2019|277
IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
|Journal of Clinical Investigation|2023|165